Ignite Creation Date:
2025-12-25 @ 1:33 AM
Ignite Modification Date:
2026-06-21 @ 2:52 PM
Study NCT ID:
NCT01816594
Status:
COMPLETED
Last Update Posted:
2019-11-14
First Post:
2013-03-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | HER2-positive Newly Diagnosed, Primary Breast Cancer | View |